In Vitro Validation of Survivin as Target Tumor-associated Antigen for Immunotherapy in Uterine Cancer
In conclusion, we currently validated the presence of survivin in uterine cancer. In addition, spontaneous T-cell responses were found in 23.6% of the total patient population. These data indicate that a survivin-specific immune response may be induced spontaneously in patients, further fortifying the eligibility of survivin as an immunotherapeutic target.
Source: Journal of Immunotherapy - Category: Allergy & Immunology Tags: Basic Studies Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Cancer of the Uterus | Carcinoma | Endometrial Cancer | Immunotherapy | Sarcomas | Study | Uterine Sarcoma